Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.
Company profile
Ticker
JNJ
Exchange
Website
CEO
Alex Gorsky
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
JOHNSON & JOHNSON ET AL
SEC CIK
Corporate docs
Subsidiaries
ABD Holding Company, Inc. • ABIOMED COMMERCIAL, LLC • ABIOMED R&D, Inc. • ABIOMED, Inc. • Acclarent, Inc. • Actelion Pharmaceuticals US, Inc. • Albany Street LLC • ALZA Corporation • Alza Land Management, Inc. • AMO Development, LLC ...
IRS number
221024240
JNJ stock data
Latest filings (excl ownership)
8-K/A
Johnson & Johnson Reports Q1 2024 Results
16 Apr 24
8-K
Johnson & Johnson Reports Q1 2024 Results
16 Apr 24
DFAN14A
Additional proxy materials by non-management
5 Apr 24
PX14A6G
Letter to shareholders
27 Mar 24
ARS
2023 FY
Annual report to shareholders
13 Mar 24
DEFA14A
Additional proxy soliciting materials
13 Mar 24
DEFA14A
Additional proxy soliciting materials
13 Mar 24
DEF 14A
Definitive proxy
13 Mar 24
10-K
2023 FY
Annual report
16 Feb 24
DFAN14A
Additional proxy materials by non-management
15 Feb 24
Transcripts
JNJ
Earnings call transcript
2024 Q1
16 Apr 24
JNJ
Earnings call transcript
2023 Q4
23 Jan 24
JNJ
Earnings call transcript
2023 Q3
17 Oct 23
JNJ
Earnings call transcript
2023 Q2
20 Jul 23
JNJ
Earnings call transcript
2023 Q1
18 Apr 23
JNJ
Earnings call transcript
2022 Q4
24 Jan 23
JNJ
Earnings call transcript
2022 Q3
18 Oct 22
JNJ
Earnings call transcript
2022 Q2
19 Jul 22
JNJ
Earnings call transcript
2022 Q1
19 Apr 22
JNJ
Earnings call transcript
2021 Q4
25 Jan 22
Latest ownership filings
SC 13G
Contineum Therapeutics, Inc.
10 Apr 24
3
Contineum Therapeutics, Inc.
10 Apr 24
4
Vanessa Broadhurst
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
Eugene A. Woods
7 Mar 24
4
MARILLYN A HEWSON
7 Mar 24
4
CVRx, Inc.
6 Mar 24
4
Jennifer L Taubert
20 Feb 24
4
Kathryn E Wengel
20 Feb 24
4
Timothy Schmid
20 Feb 24
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jan 23 | Jan 22 | Jan 21 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.73 bn | 19.73 bn | 19.73 bn | 19.73 bn | 19.73 bn | 19.73 bn |
Cash burn (monthly) | 485.00 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 3.29 bn | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 16.43 bn | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 33.9 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
51.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3250 |
Opened positions | 276 |
Closed positions | 603 |
Increased positions | 1094 |
Reduced positions | 1608 |
13F shares | Current |
---|---|
Total value | 173.84 tn |
Total shares | 1.23 bn |
Total puts | 5.13 mm |
Total calls | 4.06 mm |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 229.39 mm | $35.95 tn |
STT State Street | 132.90 mm | $20.83 tn |
MS Morgan Stanley | 41.66 mm | $6.53 tn |
Whalerock Point Partners | 35.41 mm | $5.55 bn |
JPM JPMorgan Chase & Co. | 29.75 mm | $4.66 tn |
NTRS Northern Trust | 29.73 mm | $4.66 tn |
Capital International Investors | 28.99 mm | $4.54 tn |
Wellington Management | 24.02 mm | $3.76 tn |
BK Bank Of New York Mellon | 22.23 mm | $3.48 tn |
LGEN Legal & General | 22.10 mm | $3.46 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Mar 24 | Vanessa Broadhurst | Common Stock | Sell | Dispose S | No | No | 162.16 | 8,891 | 1.44 mm | 15,043 |
5 Mar 24 | Marillyn A Hewson | Deferred Share Units Common Stock | Grant | Acquire A | No | No | 159.8 | 234.668 | 37.50 k | 8,787.744 |
5 Mar 24 | Woods Eugene A. | Deferred Share Units Common Stock | Grant | Acquire A | No | No | 159.8 | 261.993 | 41.87 k | 753.446 |
5 Mar 24 | Woods Eugene A. | Deferred Share Units Common Stock | Grant | Acquire A | No | No | 159.8 | 491.453 | 78.53 k | 491.453 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 5.141 | 79 | 406.14 | 4,103,430 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 3.955 | 252 | 996.66 | 4,103,351 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 1.186 | 142 | 168.41 | 4,103,099 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 1.186 | 442 | 524.21 | 4,102,957 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 0.237 | 300 | 71.10 | 4,102,515 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 0.237 | 584 | 138.41 | 4,102,215 |
News
Johnson & Johnson Children's Cough Syrup Contaminated In Some Batches - WHO Poised to Issue Global Alert (Updated)
23 Apr 24
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
19 Apr 24
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
19 Apr 24
Unpacking the Latest Options Trading Trends in Johnson & Johnson
18 Apr 24
Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future
17 Apr 24
Press releases
Investment Opportunities in Biotech Amidst Federal Rate Uncertainties (ATNM)
22 Apr 24
Illinois Jury Awards $45 Million in Mesothelioma Case Against Johnson & Johnson, Kenvue, Inc.
19 Apr 24
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
19 Apr 24
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
16 Apr 24
Johnson & Johnson Reports Q1 2024 Results
16 Apr 24